VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Novavax Executive Compensation (FY25)

NVAX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
John Jacobs
Median of the other named officers
$2,810,453
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 18, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Novavax

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 23, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Novavax brief$500Get the executive brief
Velarion Intel, one year, every company
299 figures on this page: 289 cited to the filing that reported them, 10 calculated from figures it prints. See the citations

More on Novavax

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Jacobs: $5,087,461 → $8,856,015 (74.1% higher)
CEO pay ratio: 32:1 → 52:1 (62.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Novavax's chief executive and what were they paid?
John Jacobs, President and CEO, received $8,856,015 in total compensation for fiscal 2025. Jacobs' total moved 74.1% higher from the $5,087,461 reported for fiscal 2024.
What was Novavax's say-on-pay result?
The say-on-pay proposal drew 50.6% support at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Novavax's peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Amphastar Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc. and Arvinas, Inc, among others.
What is Novavax's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 52:1, against median employee compensation of $169,449.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stanley Erck
Former President and CEO
◇—◇◇◇—◇◇
James Kelly
EVP, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
John Trizzino
President and Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Jacobs
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Stanley Erck
Former President and CEO
Departed during or after this year
◇——◇——◇◇
Filip Dubovsky
President, Research & Development
◇—◇◇◇—◇◇
John Trizzino
Former President and Chief Operating Officer
◇—◇◇◇—◇◇
Mark Casey
Executive Vice President, Chief Legal Officer and Corporate Secretary
◇◇◇◇——◇◇
James Kelly
Executive Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Jacobs
President and CEO
◇—◇◇◇—◇◇
James Kelly
EVP, Chief Financial Officer and Treasurer
◇—◇—◇—◇◇
Elaine O'Hara
EVP, Chief Strategy Officer
◇—◇—◇—◇◇
John Trizzino
President and Chief Operating Officer
◇—◇—◇—◇◇
Filip Dubovsky
Former President, Research & Development
Departed during or after this year
◇◇◇———◇◇
Mark Casey
EVP, Chief Legal Officer and Corporate Secretary
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Jacobs
President and CEO
◇—◇◇◇—◇◇
Elaine O'Hara
EVP, Chief Strategy Officer
◇—◇◇◇—◇◇
James Kelly
EVP, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Mark Casey
EVP, Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Ruxandra Draghia-Akli
Former EVP, Head of Research & Development
Departed during or after this year
◇—◇◇◇—◇◇
John Trizzino
Former President and Chief Operating Officer
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Elaine O HaraRSU◇——◇——◇
Elaine O HaraOPTION◇——◇—◇◇
James P. KellyOPTION◇——◇—◇◇
James P. KellyRSU◇——◇——◇
John C. JacobsRSU◇——◇——◇
John C. JacobsOPTION◇——◇—◇◇
Mark J. CaseyRSU◇——◇——◇
Mark J. CaseyOPTION◇——◇—◇◇
Ruxandra Draghia-AkliRSU◇——◇——◇
Ruxandra Draghia-AkliOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John JacobsOption◇—◇3/3/2035
RSU◇◇——
Option◇—◇3/1/2034
RSU◇◇——
RSU◇◇——
Option◇—◇1/23/2033
Elaine O'HaraOption◇—◇3/3/2035
RSU◇◇——
RSU◇◇——
Option◇—◇12/11/2033
Option◇—◇3/1/2033
RSU◇◇——
James KellyOption◇—◇3/3/2035
RSU◇◇——
RSU◇◇——
Option◇—◇3/7/2033
RSU◇◇——
Option◇—◇3/10/2032
Mark CaseyOption◇—◇3/3/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Ruxandra Draghia-AkliOption◇—◇3/3/2025
RSU◇◇——
RSU◇◇——
John TrizzinoRSU◇◇——
Option◇—◇11/11/2034
RSU◇◇——
Option◇—◇3/10/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John W. Shiver, Ph.D
◇◇◇———◇
Charles W. Newton
◇◇◇———◇
Margaret G. McGlynn, R. Ph
◇◇◇———◇
Richard J. Rodgers
◇◇◇———◇
David Mott
Board chair
◇◇◇———◇
Richard H. Douglas, Ph.D
◇◇◇———◇
Gregg H. Alton, J.D
◇◇◇———◇
Rachel K. King
◇◇◇———◇
James F. Young, Ph.D
◇—————◇
John C. Jacobs served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Amphastar Pharmaceuticals, Inc. AMPH
  • ANI Pharmaceuticals, Inc. ANIP
  • Arvinas, Inc ARVN
  • Beam Therapeutics Inc. BEAM
  • Bicycle BCYC
  • BioCryst Pharmaceuticals, Inc. BCRX
  • Corcept Therapeutics Incorporated CORT
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Denali Therapeutics Inc. DNLI
  • Dynavax Technologies Corporation DVAX
  • Emergent BioSolutions Inc. EBS
  • Intellia Therapeutics, Inc. NTLA
  • Pacira BioSciences, Inc. PCRX
  • PTC Therapeutics, Inc. PCTX
  • Sana Biotechnology, Inc. SANA
  • Supernus Pharmaceuticals, Inc. SUPN
  • Ultragenyx Pharmaceutical Inc. RARE
  • Vir Biotechnology, Inc. VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 20, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022July 11, 2023=◇◇◇
2021June 16, 2022=◇◇◇
2020June 17, 2021=◇◇◇
2019June 25, 2020=◇◇◇
2018June 28, 2019=◇◇◇
2017June 14, 2018=◇◇◇
2016June 15, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Jacobs (President and CEO), FY2025 total compensation $8,856,015 (base salary $792,917) [exec_comp, SEC accession 0001628280-26-027328, filed 2026-04-27]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Novavax files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Novavax disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Novavax sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Novavax recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Novavax's disclosed peer group is defensible, who names Novavax back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
299 figures on this page: 289 cited to the filing that reported them, 10 calculated from figures it prints.
289 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-26-076648
  2. 0001628280-26-027328
    Compensation of Directors · DIRECTOR COMPENSATION TABLE · Grants of Plan-Based Awards Table · Outstanding Equity Awards at 202 · and 2 more sections
  3. 0001104659-25-061874
  4. 0001000694-25-000013
    Summary Compensation Table
  5. 0001104659-24-071735
  6. 0001000694-24-000020
    Summary Compensation Table
  7. 0001104659-23-080024
  8. 0001104659-22-072966
  9. 0001104659-21-085176
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001104659-20-077556
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001144204-19-033618
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001144204-18-034442
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001144204-17-032891
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Novavax executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NVAX (accessed 2026).
Short form: data: Velarion

The paid brief for Novavax

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Novavax and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Novavax discloses

The companies named in NVAX's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAmphastar Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc.Arvinas, IncBeam Therapeutics Inc.BicycleBioCryst Pharmaceuticals, Inc.Corcept Therapeutics IncorporatedCrinetics Pharmaceuticals, Inc.Denali Therapeutics Inc.Dynavax Technologies CorporationEmergent BioSolutions Inc.Intellia Therapeutics, Inc.Pacira BioSciences, Inc.Sana Biotechnology, Inc.Supernus Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.Vir Biotechnology, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy